Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: GlobeNewswire
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. The fireside chat details are as follows: Date: Wednesday, February 11, 2026Time: 1:00pm (ET) Location: Lotte New York Palace, New York CityWebcast link: Investor Presentations - Inventiva Pharma About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatm
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Inventiva (NASDAQ:IVA) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Inventiva (NASDAQ:IVA) was given a new $24.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.MarketBeat
- Inventiva (NASDAQ:IVA) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Inventiva (NASDAQ:IVA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Inventiva (NASDAQ:IVA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
IVA
Earnings
- 9/29/25 - Miss
IVA
Sec Filings
- 1/30/26 - Form SCHEDULE
- 11/28/25 - Form 6-K
- 11/24/25 - Form 6-K
- IVA's page on the SEC website